New drug for moderate-to-severe rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests an investigational drug, QLS12010, for people with moderate-to-severe rheumatoid arthritis who have not improved enough after trying at least two other types of RA medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with rheumatoid arthritis for at least 12 weeks.
- You have at least 4 tender and 4 swollen joints.
- You have had an inadequate response to at least one conventional DMARD and one biologic or targeted synthetic DMARD.
- If you take steroids (like prednisone), the dose is 10 mg or less per day and has been stable for at least 2 weeks before starting the trial.
- You do not have other types of inflammatory arthritis, a history of certain cancers, untreated recurrent migraines, or serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, QLS12010, to see if it is safe and how it works in healthy volunteers and in people with moderate to severe atopic dermatitis (eczema). It may offer a new treatment option for those whose eczema has not improved with topical creams.
This study tests an investigational drug called TLL-018 for people with moderate to severe rheumatoid arthritis who have not improved enough with standard disease-modifying drugs. It aims to see if the drug can reduce joint pain and swelling.
This trial tests an investigational drug called JAB-8263 for people with active rheumatoid arthritis. It aims to see if the drug can help reduce inflammation and improve symptoms.
This trial tests a new medicine called CLN-978, given as an injection under the skin, to see if it can help people with active rheumatoid arthritis who haven't improved enough with other treatments. CLN-978 works by targeting a specific immune cell to reduce inflammation.
This trial tests a new drug, LPX-TI641, to see if it is safe and how it works in the body for people with rheumatoid arthritis or psoriatic arthritis. It may be an option if you have active joint swelling and pain despite standard treatments.
This study tests an investigational drug called SAR448501/DR-0201 in people with active lupus or rheumatoid arthritis who have not responded well to standard treatments. The goal is to see if the drug is safe and helps control disease activity.
Hear when a new Rheumatoid Arthritis (RA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.